PMID- 37584872
OWN - NLM
STAT- MEDLINE
DCOM- 20231002
LR  - 20231002
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 28
IP  - 10
DP  - 2023 Oct
TI  - Retrospective study of the efficacy and safety of docetaxel/carboplatin 
      combination therapy as postoperative adjuvant chemotherapy for nonsquamous cell 
      carcinoma of the cervix.
PG  - 1421-1430
LID - 10.1007/s10147-023-02392-0 [doi]
AB  - OBJECTIVE: Optimal adjuvant chemotherapy for nonsquamous cervical carcinoma has 
      not yet been established. This study investigated the efficacy and safety of 
      docetaxel/carboplatin (DC) for early-stage nonsquamous cell cervical carcinoma 
      after radical hysterectomy (RH). METHODS: We evaluated 157 patients with stage 
      IB-IIB nonsquamous cervical carcinoma with intermediate risk and high risk 
      treated at our institution with DC after type II or III RH from 2007 to 2021. 
      Patients received docetaxel (60-70 mg/m(2)) and carboplatin (area under the curve 
      5-6) every 3 weeks for six cycles. The primary endpoint was 2 year 
      recurrence-free survival (RFS) and the secondary endpoint was adverse events 
      (AEs). RESULTS: There were 106 intermediate-risk and 51 high-risk patients. The 
      high-risk patients included 11 with positive parametrial involvement, 20 with 
      pelvic lymph node metastases, and 20 with both parametrial involvement and pelvic 
      lymph node metastases. The 2 year RFS rates for intermediate-risk, high-risk, and 
      positive pelvic lymph nodes were 94.8% (95% confidence interval [CI], 87.9-97.8), 
      80.1% (95% CI, 64.1-89.5), and 74.5% (95% CI, 55.4-86.4), respectively. Sixteen 
      patients had recurrence, including local recurrence (n = 6), distant metastasis 
      (n = 9), and local and distant metastasis (n = 1). Hematologic toxicity was the 
      most frequent AE, especially leukopenia and neutropenia. Nausea and constipation 
      were the most frequent nonhematologic toxicities. CONCLUSION: DC therapy at our 
      institution showed good 2 year RFS, and postoperative adjuvant therapy with DC 
      therapy is suggested as a useful strategy for patients with nonsquamous cervical 
      carcinoma.
CI  - (c) 2023. The Author(s) under exclusive licence to Japan Society of Clinical 
      Oncology.
FAU - Koike, Ryo
AU  - Koike R
AUID- ORCID: 0009-0003-4565-2360
AD  - Department of Obstetrics and Gynecology, Showa University School of Medicine, 
      Tokyo, Japan.
AD  - Department of Gynecologic Oncology, Cancer Institute hospital of JFCR, Tokyo, 
      Japan.
FAU - Yunokawa, Mayu
AU  - Yunokawa M
AUID- ORCID: 0000-0001-7354-6977
AD  - Department of Gynecologic Oncology, Cancer Institute hospital of JFCR, Tokyo, 
      Japan. mayu.yunokawa@jfcr.or.jp.
FAU - Omatsu, Kohei
AU  - Omatsu K
AUID- ORCID: 0000-0003-4897-5029
AD  - Department of Gynecologic Oncology, Cancer Institute hospital of JFCR, Tokyo, 
      Japan.
FAU - Kurihara, Nozomi
AU  - Kurihara N
AUID- ORCID: 0009-0007-6888-4358
AD  - Department of Clinical Trial Planning and Management, Cancer Institute Hospital, 
      Tokyo, Japan.
FAU - Nomura, Hidetaka
AU  - Nomura H
AUID- ORCID: 0000-0002-2742-5282
AD  - Department of Gynecologic Oncology, Cancer Institute hospital of JFCR, Tokyo, 
      Japan.
FAU - Kanao, Hiroyuki
AU  - Kanao H
AUID- ORCID: 0000-0003-1372-6145
AD  - Department of Gynecologic Oncology, Cancer Institute hospital of JFCR, Tokyo, 
      Japan.
FAU - Sekizawa, Akihiko
AU  - Sekizawa A
AUID- ORCID: 0000-0003-2249-1333
AD  - Department of Obstetrics and Gynecology, Showa University School of Medicine, 
      Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230816
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - BG3F62OND5 (Carboplatin)
RN  - 15H5577CQD (Docetaxel)
SB  - IM
MH  - Female
MH  - Humans
MH  - Carboplatin
MH  - Retrospective Studies
MH  - Docetaxel/therapeutic use
MH  - Cervix Uteri/pathology
MH  - Lymphatic Metastasis
MH  - Chemotherapy, Adjuvant
MH  - *Carcinoma/drug therapy
MH  - *Uterine Cervical Neoplasms/drug therapy/surgery/pathology
MH  - Hysterectomy
MH  - Neoplasm Staging
MH  - Survival Rate
OTO - NOTNLM
OT  - Adjuvant chemotherapy
OT  - Cervical cancer
OT  - Nonsquamous carcinoma
EDAT- 2023/08/16 12:43
MHDA- 2023/10/02 06:42
CRDT- 2023/08/16 11:12
PHST- 2023/04/23 00:00 [received]
PHST- 2023/07/20 00:00 [accepted]
PHST- 2023/10/02 06:42 [medline]
PHST- 2023/08/16 12:43 [pubmed]
PHST- 2023/08/16 11:12 [entrez]
AID - 10.1007/s10147-023-02392-0 [pii]
AID - 10.1007/s10147-023-02392-0 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2023 Oct;28(10):1421-1430. doi: 10.1007/s10147-023-02392-0. 
      Epub 2023 Aug 16.